Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Iovance Biotherapeutics's profit margin for the twelve months ending Jun 30, 2026 was -89.1%. For fiscal 2025 it was -148.4%, against -226.8% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -148.4% | +78.5 |
| FY2024 | Dec 31, 2024 | -226.8% | +37118.6 |
| FY2023 | Dec 31, 2023 | -37345.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -47.6% | +138.6 |
| Q1 FY2026 | Mar 31, 2026 | -110.7% | +124.8 |
| Q4 FY2025 | Dec 31, 2025 | -82.9% | +23.7 |
| Q3 FY2025 | Sep 30, 2025 | -135.3% | +7.4 |
| Q2 FY2025 | Jun 30, 2025 | -186.2% | +125.9 |
| Q1 FY2025 | Mar 31, 2025 | -235.5% | +15565.3 |
| Q4 FY2024 | Dec 31, 2024 | -106.6% | +24038.4 |
| Q3 FY2024 | Sep 30, 2024 | -142.7% | +24113.2 |
| Q2 FY2024 | Jun 30, 2024 | -312.2% | +44447.5 |
| Q1 FY2024 | Mar 31, 2024 | -15800.8% | – |
| Q4 FY2023 | Dec 31, 2023 | -24145.0% | – |
| Q3 FY2023 | Sep 30, 2023 | -24255.9% | – |
| Q2 FY2023 | Jun 30, 2023 | -44759.7% | – |
See a number that looks wrong?